T 0145/22 (Oral azacytidine/CELGENE) of 26.07.2024
- European Case Law Identifier
- ECLI:EP:BA:2024:T014522.20240726
- Date of decision
- 26 July 2024
- Case number
- T 0145/22
- Petition for review of
- -
- Application number
- 09746975.3
- IPC class
- A61K 31/7068A61K 9/20A61K 9/28
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- ORAL FORMULATIONS OF CYTIDINE ANALOGS AND METHODS OF USE THEREOF
- Applicant name
- Celgene Corporation
- Opponent name
- Teva Pharmaceutical Industries Ltd
Generics (UK) Ltd - Board
- 3.3.07
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 111European Patent Convention Art 123(2)European Patent Convention Art 54European Patent Convention Art 56Rules of procedure of the Boards of Appeal 2020 Art 012(3)Rules of procedure of the Boards of Appeal 2020 Art 012(4)Rules of procedure of the Boards of Appeal 2020 Art 013(1)Rules of procedure of the Boards of Appeal Art 11
- Keywords
- Amendments - allowable (yes)
Novelty - (yes)
Remittal - (no)
Inventive step - (yes) non-obvious modification
Amendment to case - amendment admitted (yes) - Catchword
- -
Order
For these reasons it is decided that:
1. The decision under appeal is set aside.
2. The patent is maintained as granted.